Nevro Corp Company Leadership
NVRO Stock | USD 4.55 0.03 0.66% |
Nevro Corp's insiders are aggressively buying. The analysis of insiders' sentiment of trading Nevro Corp stock suggests that virtually all insiders are extremely bullish at this time. Nevro Corp employs about 1.2 K people. The company is managed by 33 executives with a total tenure of roughly 119 years, averaging almost 3.0 years of service per executive, having 36.82 employees per reported executive.
DKeith Grossman Chairman Chairman of the Board, President, Chief Executive Officer |
Christopher Christoforou President Vice President - Research and Development |
Nevro Corp's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2023-06-07 | Shawn Mccormick | Acquired 7500 @ 22.88 | View | ||
2022-05-09 | Kashif Rashid | Acquired 2250 @ 44.5 | View | ||
2022-03-11 | Kashif Rashid | Acquired 1500 @ 64.04 | View | ||
2022-03-08 | D Keith Grossman | Acquired 3200 @ 63.59 | View | ||
2021-12-14 | Kevin C Oboyle | Acquired 2400 @ 83.78 | View |
Monitoring Nevro Corp's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Nevro |
Nevro Corp's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Nevro Corp's future performance. Based on our forecasts, it is anticipated that Nevro will maintain a workforce of about 1220 employees by December 2024.Nevro Corp Management Team Effectiveness
The company has return on total asset (ROA) of (0.0902) % which means that it has lost $0.0902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2478) %, meaning that it created substantial loss on money invested by shareholders. Nevro Corp's management efficiency ratios could be used to measure how well Nevro Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.17. In addition to that, Return On Capital Employed is likely to drop to -0.19. At this time, Nevro Corp's Non Current Assets Total are very stable compared to the past year. As of the 26th of November 2024, Intangible Assets is likely to grow to about 33 M, while Total Assets are likely to drop about 461.8 M.As of the 26th of November 2024, Net Income Applicable To Common Shares is likely to grow to about 2.8 M, while Common Stock Shares Outstanding is likely to drop about 26.7 M.
Nevro Corp Workforce Comparison
Nevro Corp is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 26,686. Nevro Corp holds roughly 1,215 in number of employees claiming about 5% of equities under Health Care industry.
Nevro Corp Profit Margins
The company has Profit Margin (PM) of (0.17) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.16) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.16.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.53 | 0.6822 |
|
|
Nevro Corp Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nevro Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nevro Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Nevro Corp insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 0.3 | 3 | 10 | 11,056 | 17,684 |
2024-06-01 | 0.6111 | 11 | 18 | 160,692 | 111,525 |
2024-03-01 | 0.875 | 14 | 16 | 441,330 | 29,266 |
2023-12-01 | 0.5714 | 4 | 7 | 3,648 | 12,006 |
2023-09-01 | 1.0 | 5 | 5 | 16,664 | 10,034 |
2023-06-01 | 1.5455 | 17 | 11 | 385,425 | 171,967 |
2023-03-01 | 0.8 | 8 | 10 | 133,767 | 29,280 |
2022-12-01 | 1.6667 | 5 | 3 | 12,691 | 3,081 |
2022-09-01 | 4.0 | 4 | 1 | 1,684 | 4,365 |
2022-06-01 | 4.6667 | 14 | 3 | 41,408 | 6,288 |
2022-03-01 | 1.5 | 12 | 8 | 266,240 | 141,594 |
2021-12-01 | 4.5 | 9 | 2 | 25,342 | 7,011 |
2021-09-01 | 2.5 | 5 | 2 | 9,997 | 9,240 |
2021-06-01 | 1.6667 | 10 | 6 | 8,547 | 18,096 |
2021-03-01 | 0.7143 | 10 | 14 | 49,002 | 17,387 |
2020-12-01 | 0.5333 | 8 | 15 | 4,578 | 36,939 |
2020-09-01 | 0.24 | 6 | 25 | 2,055 | 141,042 |
2020-06-01 | 3.25 | 13 | 4 | 54,399 | 8,791 |
2020-03-01 | 0.7647 | 13 | 17 | 82,593 | 140,694 |
2019-12-01 | 0.35 | 7 | 20 | 33,724 | 125,844 |
2019-09-01 | 2.0 | 6 | 3 | 107,932 | 7,276 |
2019-06-01 | 6.5 | 13 | 2 | 48,510 | 3,590 |
2019-03-01 | 1.75 | 7 | 4 | 242,498 | 15,955 |
2018-12-01 | 1.6 | 8 | 5 | 114,750 | 9,300 |
2018-09-01 | 0.8 | 4 | 5 | 28,300 | 29,164 |
2018-06-01 | 1.8 | 9 | 5 | 37,126 | 25,914 |
2018-03-01 | 0.05 | 1 | 20 | 7,000 | 217,019 |
2017-12-01 | 1.7 | 17 | 10 | 342,822 | 66,073 |
2017-09-01 | 0.1515 | 5 | 33 | 7,040 | 238,926 |
2017-06-01 | 0.8571 | 18 | 21 | 59,441 | 133,731 |
2017-03-01 | 0.36 | 9 | 25 | 217,839 | 161,600 |
2016-12-01 | 0.6757 | 25 | 37 | 287,034 | 349,028 |
2016-09-01 | 0.0923 | 6 | 65 | 12,000 | 442,500 |
2016-06-01 | 0.3778 | 17 | 45 | 72,207 | 258,780 |
2016-03-01 | 0.3226 | 10 | 31 | 438,408 | 141,987 |
2015-12-01 | 0.5957 | 28 | 47 | 292,422 | 329,453 |
2015-09-01 | 0.125 | 1 | 8 | 4,000 | 48,001 |
2015-06-01 | 1.0 | 8 | 8 | 67,445 | 2,387,403 |
2014-12-01 | 1.1667 | 35 | 30 | 13,908,967 | 11,115,709 |
2014-06-01 | 1.0 | 1 | 1 | 58,906 | 58,906 |
Nevro Corp Notable Stakeholders
A Nevro Corp stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nevro Corp often face trade-offs trying to please all of them. Nevro Corp's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nevro Corp's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kevin Thornal | CEO President | Profile | |
DKeith Grossman | Chairman of the Board, President, Chief Executive Officer | Profile | |
D Grossman | Chairman of the Board, President, Chief Executive Officer | Profile | |
Christopher Christoforou | Vice President - Research and Development | Profile | |
Patrick Schmitz | Vice President - Operations | Profile | |
Roderick MacLeod | Chief Financial Officer | Profile | |
Elizabeth Weatherman | Independent Director | Profile | |
Brad Vale | Independent Director | Profile | |
Kevin OBoyle | Independent Director | Profile | |
Shawn McCormick | Independent Director | Profile | |
Frank Fischer | Independent Director | Profile | |
Michael DeMane | Lead Independent Director | Profile | |
Susan Siegel | Independent Director | Profile | |
Peter Socarras | General VP | Profile | |
Geeta Kaveti | VP Officer | Profile | |
Julie Dewey | Vice President - Investor Relations and Corporate Communications | Profile | |
Donald Middlebrook | Vice President - Clinical, Regulatory and Quality | Profile | |
Meredith Vornholt | Vice Marketing | Profile | |
Kashif JD | Senior Officer | Profile | |
David Caraway | Chief Medical Officer | Profile | |
Christofer Christoforou | Senior Operations | Profile | |
Richard Carter | Chief Officer | Profile | |
Sridhar Kosaraju | Director | Profile | |
Greg Siller | Senior Officer | Profile | |
Shana MBA | Senior Officer | Profile | |
Michael Carter | Vice President - Global Sales | Profile | |
Karen Prange | Independent Director | Profile | |
Angeline McCabe | Vice Communications | Profile | |
Kashif Rashid | Chief Compliance Officer, General Counsel, Corporate Secretary | Profile | |
Niamh Pellegrini | Chief Commercial Officer | Profile | |
Lori Ciano | Chief Human Resource Officer | Profile | |
David MD | Senior Officer | Profile | |
Jon Shear | Senior Development | Profile |
About Nevro Corp Management Performance
The success or failure of an entity such as Nevro Corp often depends on how effective the management is. Nevro Corp management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nevro management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nevro management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.16) | (0.17) | |
Return On Capital Employed | (0.18) | (0.19) | |
Return On Assets | (0.15) | (0.15) | |
Return On Equity | (0.31) | (0.33) |
Nevro Corp Workforce Analysis
Traditionally, organizations such as Nevro Corp use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nevro Corp within its industry.Nevro Corp Manpower Efficiency
Return on Nevro Corp Manpower
Revenue Per Employee | 349.9K | |
Revenue Per Executive | 12.9M | |
Net Loss Per Employee | 75.9K | |
Net Loss Per Executive | 2.8M | |
Working Capital Per Employee | 368.4K | |
Working Capital Per Executive | 13.6M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nevro Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Nevro Stock, please use our How to Invest in Nevro Corp guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nevro Corp. If investors know Nevro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nevro Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.87) | Revenue Per Share 11.404 | Quarterly Revenue Growth (0.07) | Return On Assets (0.09) | Return On Equity (0.25) |
The market value of Nevro Corp is measured differently than its book value, which is the value of Nevro that is recorded on the company's balance sheet. Investors also form their own opinion of Nevro Corp's value that differs from its market value or its book value, called intrinsic value, which is Nevro Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nevro Corp's market value can be influenced by many factors that don't directly affect Nevro Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nevro Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nevro Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nevro Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.